18.04.2024 14:38:37 - dpa-AFX: *ABBVIE'S PHASE 3 STUDY OF UPADACITINIB SHOWS POSITIVE RESULTS IN GIANT CELL ARTERITIS PATIENTS

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
ABBVIE INC. DL-,01 A1J84E Xetra 160,860 21.06.24 15:40:07 +0,380 +0,24% 160,660 160,940 160,200 160,480

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH